



These additions apply to Exchange formularies and are effective 6/16/23

Additions:

Auvelity (dextromethorphan/bupropion) – Pharmacy Benefit, Non-Preferred brand, ST and QL of 2 per day.

Jaypirca (pirtobrutinib) – Pharmacy Benefit, Non-Preferred brand, PA and QL of 3 per day for 100mg and 1 per day for 50mg.

Orserdu (elacestrant) – Pharmacy Benefit, Non-Preferred brand, PA and QL of 1 per day.

Lamzedo (velmanase alfa-tycv) – Medical Benefit, PA

Syfovre (pegcetacoplan) – Medical Benefit, PA

Briumvi (ublituximab-xiyy) – Medical Benefit, PA

Lunsumio (mosunetuzumab-axgb) – Medical Benefit, PA